LentiGlobin BB305 gene therapy regulatory update

EMA granted PRIority MEdicines (PRIME) designation to bluebird’s LentiGlobin BB305 gene therapy to treat transfusion-dependent beta-thalassemia. Earlier this month, bluebird began a Phase III trial of...